Načítá se...
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
BACKGROUND: Trials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have been observed in patients without overt heart failure, but it is unclear...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3180261/ https://ncbi.nlm.nih.gov/pubmed/21910880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1532-429X-13-45 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|